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1. Introduction 
Uterine leiomyomas are the most common benign pelvic tumors in women [1, 2]. They are 
monoclonal tumors of the smooth muscle cells of the myometrium and consist of large 
amounts of extracellular matrix that contains collagen, fibronectin and proteoglycan [2, 3]. A 
thin pseudocapsule that is composed of areolar tissue and compressed muscle fibers usually 
surrounds the tumors [4]. Leiomyomas may enlarge to cause significant distortion of the 
uterine surface or cavity. Although they are benign, they commonly result in severe 
symptoms, such as heavy, irregular and prolonged menstrual bleeding as well as anemia. 
Uterine leiomyomas have also been associated with numerous other medical disorders, such 
as infertility, recurrent abortion and preterm labor [5]. These clinical complications 
negatively impact women’s health. Uterine leiomyomas are the most cited indication for 
more than 600,000 hysterectomies performed in the US annually, and this major surgery is 
associated with morbidity and mortality as well as a huge economic impact on healthcare 
delivery systems that is estimated to be approximately $2.2 billion/year [6].  
2. Current medical treatment options for uterine leiomyomas  
Treatment options for leiomyoma vary. Treatment strategies are typically individualized 
based on the severity of the symptoms, the size and location of the leiomyoma lesions, the 
patient’s age and their chronological proximity to menopause, and the patient’s desire for 
future fertility. The usual goal of therapy is the relief of the symptoms (which include 
abnormal uterine bleeding, pain, and pressure). The treatment options range from the use of 
acupuncture (ancient Chinese method) to the total removal of the uterus and its myoma 
contents [7]. The gold standard of leiomyoma treatment is surgical intervention. 
Hysterectomy is the definitive surgical operation, but myomectomy is still commonly 
performed especially in women who desire future fertility. More recently developed 
techniques, which include uterine artery embolization (UAE), magnetic resonance-guided 
focused-ultrasound surgery (MRgFUS) and myolysis, are emerging as minimally invasive 
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alternative procedures. To date, there is no definitive therapeutic agents for the treatment of 
uterine leiomyomas, which is a reflection of the dearth of randomized clinical trial data 
demonstrating the effectiveness and safety of medical therapies in the management of 
symptomatic leiomyomas [8]. This chapter will focus on medical treatment options for 
uterine leiomyoma as a promising tool to decrease the rate of hysterectomy with its burden 
to the health system as well as the patients.  
2.1 COCs and progestins 
Combined oral contraceptive hormones have been widely tried by physicians to reduce the 
blood loss associated with uterine fibroids. A large prospective study including more than 
3000 patients with fibroids found a positive correlation between the early use of COCs 
(before 17 years) and the incidence of fibroid [9]. Other controlled trials showed no 
association between the use of COCs and the development of uterine fibroids [10, 11]. 
The effect of COcs and progestins in reducing the size of fibroids is not documented [12-14]. 
3. Levonorgestrel-releasing intrauterine system 
The levonorgestrel-releasing intrauterine system (LNG) is one of the most effective 
treatments in reducing menorrhagia. In a small randomized trial; LNG decreased the blood 
loss significantly after 6 weeks of application in women with menorrhagia and fibroid [15]. 
However; it did not decrease the myoma size. 
3.1 Promising GnRH antagonist (elagolix) 
Elagolix is a second generation new non-peptide (GnRH) antagonist, highly potent 
antagonist orally active and rapidly bioavailable after administration that is being 
developed by Abbott Laboratories (Abbott) in collaboration with Neurocrine Biosciences 
[16, 17]. It Finalizing the Phase III for endometriosis and finalizing Phase II for uterine 
leiomyoma with opportunity to be its first and only approved oral treatment for uterine 
leiomyoma [18]. This promising compound inhibits gonadotropin releasing hormone 
(GnRh) receptors in the pituitary gland leading to a dose dependent suppression of LH, FSH 
and estradiol. Consequently, suppression of E2 is more prolonged at higher doses. Pituitary 
suppression is maintained for only a portion of the day, and baseline gonadotropin levels 
return by 24 hours [19]. 
These properties suggest that elagolix may enable dose-related pituitary and gonadal 
suppression in premenopausal women as part of treatment strategies for reproductive 
hormone-dependent disease states [19]. To date, elagolix has been studied in 18 clinical trials 
totaling more than 1,000 subjects.  
Elagolix seems to be well tolerated for multiple-doses up to 200; rapidly absorbed after oral 
administration, with median time of maximum plasma concentration (Tmax) values ranging 
from 0.5–1 h, the primary metabolite (NBI-61962) appear in the serum rapidly after 
administration [19].  
The therapeutic window of E2 levels for suppression of endometriosis using is attainable at 
a dose of 100-150mg/day with serum estradiol remained between 20 – 50 pg/ml [20]. This is 
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supported by Barberi RL findings which showed that E2 levels between 30-50 pg/ml are 
effective in inducing endometrial atrophy [21]. The Elagolix therapeutic dose for 
management of uterine fibroid has yet to be determined.  
4. Selective Estrogen Receptor Modulators (SERMS) 
Selective estrogen receptor modulators (SERMs) are non-steroidal estrogen receptor ligands 
that display tissue-specific agonist–antagonist estrogenic actions. They are used frequently 
in the treatment and prevention of estrogen receptor-positive carcinoma of the breast in 
addition to their use as ovulation induction agents [22, 23]. Tamoxifen is one of the oldest 
known SERMs, but it may potentially cause endometrial carcinoma due to its partial 
agonistic effect on the endometrium [24]. There are no randomized controlled trials that 
have investigated the potential role of Tamoxifen in the treatment of uterine fibroids; 
however, a few case reports have suggested that it actually increases leiomyoma growth [22, 
25]. Raloxifene is another SERM that can be theoretically considered to be a candidate 
therapeutic option for uterine fibroids. Raloxifene only slightly affected collagen 
biosynthesis in control myometrium cells; however, it significantly inhibited collagen 
biosynthesis in leiomyoma cells [26] and exerted its action at the transcriptional level [27]. A 
newly developed SERM, “Lasofoxifene”, is currently awaiting FDA approval. However, the 
results of early trials suggest that there were no significant benefits compared to raloxifene 
for the skeleton, breast, heart, or reproductive tract [28, 29].  
4.1 Mechanism of action  
The most probable hypothesis that explain SERMs’ mechanism of action is that they induce 
changes in estrogen receptors, which result in differential expression of specific estrogen-
regulated genes in different tissues [30]. Every member of the SERM family has its own 
individual characteristics, which depend on its structure, the type of estrogen receptor they 
bind to, and the set of molecules that interact with its estrogen receptor/SERM complex in 
affected cells, and these characteristics result in either agonistic or antagonistic activity [31]. 
SERMS could potentially provide therapeutic benefits by having antagonistic effects at 
uterine myometrial level and by preventing ovarian stimulation which has been achieved in 
rat studies. The difference in activity of SERMS is based on the structure activity 
relationships (SAR) [32].  
4.2 SERMs and treatment of uterine fibroids  
All SERMs, with their estrogen blocking activity, would be theoretically expected to exert at 
least some therapeutic effect on uterine fibroids. Raloxifene has been showed to enhance the 
shrinkage of uterine fibroids in postmenopausal women [33, 34]. However, a recent report 
from Italy that addressed the effect of raloxifene on uterine leiomyoma showed that the 
leiomyoma size in premenopausal women who were administered daily 60-mg doses of 
raloxifene over a 2-year period exhibited no change in leiomyoma size [35]. 
4.3 Adverse events  
Tamoxifen is not recommended for women with a prior history of deep venous thrombosis, 
pulmonary embolus, stroke, or transient ischemic attack because it increases the risk of 
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ischemic stroke, particularly in women who are 50 years of age or older. Additionally, the risk 
of uterine/endometrial cancer was approximately doubled with tamoxifen use [36], and the 
risk of superficial thrombophlebitis was three times higher [24, 37]. Some of these side effects 
could be explained by the inhibition of cellular glutamine uptake, oxidative stress and the 
induction of apoptosis [38]. SERMs are seldom used for the treatment of uterine fibroids [26]. 
5. Aromatase inhibitors 
Aromatase inhibitors (AI) significantly block both ovarian and peripheral estrogen 
production within 1 day of treatment [39]. Letrozole suppressed the production of 
estrogens, particularly estrone and estradiol, by 76-79% compared to their baseline levels 
[40]. The underlying mechanism is the inhibition of the aromatase enzyme, which is the 
enzyme that catalyzes the conversion of androgenic substances into estrogens [41]. Recent 
reports have suggested that aromatase is expressed to a greater extent in uterine leiomyoma 
tissues of African-American women compared to Caucasian women, which may contribute 
to the higher incidence of ULMs in African American women [42]. Aromatase inhibitors 
have been shown to be effective against fibroids in limited short term studies with dosing 
regimens that included 2.5 mg per day of letrozole and 1 mg per day of anastrozole [43]. 
One of the major concerns with the use of aromatase inhibitors is the reported bone loss 
with prolonged use, which necessitates the concomitant use of oral contraceptive pills or 
progesterone [44]. A recently published RCT compared the effects of three months of 
aromatase inhibitor (letrozole) to that of three months of gonadotropin-releasing hormone 
agonist (triptorelin) on uterine leiomyoma volume and hormonal status [45]. The results 
showed an advantage of the rapid onset of action of AIs in addition to the avoidance of the 
flare ups that initially occurs with GnRHa. Both treatment options induced significant 
shrinkage of the uterine fibroids and improvement in leiomyoma-associated symptoms [45]. 
The mean reduction of leiomyoma volume with 3 months use of anastrazole is 55.7% [46]. 
The authors suggested that aromatase inhibitors should be considered in women with 
fibroids on a short term basis or in women who want to avoid surgical intervention to 
preserve their potential fertility [47]. Another concern with the use of AIs as a treatment 
option for uterine leiomyoma is its off-label use, which mandates a thorough review with 
patients prior to the initiation of the therapy [44]. Several RCTs are underway that would 
hopefully add to our understanding of the potential promising role of AIs in the treatment 
of uterine leiomyomas [36].  
6. Antiprogesterones 
Estrogen has traditionally been considered to be the most important stimulus for leiomyoma 
growth and numerous studies that included cell culture and animal models supported this 
concept [48]. Surprisingly, recent findings suggest that volume maintenance and growth of 
human ULMs are also heavily progesterone-dependent, and hence anti-progesterone could 
reverse leiomyoma growth effects [16, 49]. One potential link between the effects of the two 
key steroid hormones on ULMs is that estradiol induced the expression of the progesterone 
receptor and supported progesterone action on leiomyoma tissue [48]. Clinical findings also 
support these laboratory observations; studies have involved the evaluation of mifepristone 
(RU 486) [50-52], azoprisnil [43, 49], and more recently, CDB-2914 and CDB-4124 (CDB: 
Contraceptive Development Branch) [53].  
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6.1 Mifepristone  
Mifepristone (RU486), a well-known oral anti-progesterone compound, has been used for 
more than 20 years for multiple clinical indications [45, 54-56]. It has recently been evaluated as 
a potential therapeutic agent for uterine fibroids with a dose that ranges from 5 mg to 50 mg 
over a 3-month period [29, 57, 58]. Mifepristone reduced leiomyoma size (26% to 74%) and 
improved leiomyoma-related symptoms (63% to 100% induction of amenorrhea). Reported 
side effects included transient elevations in transaminases, which occurred in 4% of cases as 
well as endometrial hyperplasia and was detected in 28% of the women who were screened 
with endometrial biopsies [59]. However, these studies were mostly preliminary with limited 
numbers of subjects and therefore, larger randomized well-controlled trials that include 
thorough monitoring of liver function and endometrial histology are required to conclusively 
determine the safety and efficacy of this treatment modality.  
6.2 Asoprisnil 
Asoprisnil (J867, BAY86-5294) is an investigational selective progesterone receptor 
modulator (SPRM) that was developed for the treatment of progesterone-sensitive 
myomata. It induces unique morphological changes and is associated with inhibited 
proliferation of the endometrium and leiomyomata. These changes may lead to amenorrhea, 
which is usually encountered with its use [43, 60, 61]. Asoprisnil is a tissue selective 
molecule that binds to the progesterone receptors with a three-fold greater affinity than 
endogenous progesterone [57]. It reduces the uterine and leiomyoma volumes in a dose-
dependent manner while achieving remarkable decreases in menorrhagia scores in women 
with menorrhagia [62]. Amenorrhea rates also increased as the dose of asoprisnil was 
increased [58, 60]. When asoprisnil was administered daily for longer than 3-4 months, 
significant endometrial thickening and unusual histological appearance of the endometrial 
glands occurred [29]. 
6.3 Telapristone acetate/ CDB-4124 (proposed trade names, proellex, progenta) 
CDB-4124 is another SPRM, but it is a relatively pure progesterone antagonist. It was 
studied in recent years for the treatment of uterine fibroids and is still being evaluated to 
address its safety and dose parameters in premenopausal women [63]. Limited information 
or publications are currently available on the various clinical trials that have investigated 
CDB-4124; these studies have either been completed or were terminated due to adverse 
liver-related events according to the www.clinical trials.gov website. New clinical trials 
using lower doses of CDB-4124 have recently been approved by the FDA.  
6.4 Ulipristal/CDB-2914 (VA 2914, ellaOne, ella) 
Ulipristal is an FDA-approved selective progesterone receptor modulator (SPRM) that is 
indicated for emergency contraception. It is structurally similar to mifepristone and seems to 
be effective in the treatment of uterine fibroids. It is associated with a reduction in pain, 
bleeding and leiomyoma size between 17-24% [64], as well as an improvement in quality of 
life [65]. However, data on long-term treatment are lacking and similar to other SPRMs, 
ulipristal may be associated with endometrial thickening and endometrial hyperplasia [29, 
39, 66]. Large randomized well-controlled clinical trials are needed to evaluate the utility of 
ulipristal for potential clinical treatment of uterine fibroids [39].  
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7. Somatostatin analogues 
Increasing evidence has demonstrated a role for growth factors, such as insulin growth 
factor I (IGF-I) and IGF-II, in the initiation and progression of uterine fibroids [67-70]. 
Leiomyoma tissue expresses higher levels of IGF-I/IGF-II receptors compared to normal 
adjacent myometrium [62, 69]. Additionally, these tissues secrete their own IGF-1, probably 
for autocrine and paracrine use [70]. From a clinical perspective, it has been recently 
reported that patients with high levels of growth hormone (acromegalic patients) have a 
higher prevalence of uterine fibroids than the general population [71]. Lanreotide, which is a 
long-acting somatostatin analogue that has been shown to reduce growth hormone 
secretion, has also recently been evaluated in seven women with uterine fibroids in Italy 
[72]. Interestingly, lanreotide induced a 42% mean myoma volume reduction within a 3-
month period. These results show that somatostatin analogues may potentially be a new 
therapy for uterine fibroids [73]. The treatment with somatostatin analogues for diseases 
other than leiomyoma appears to be safe and is usually well tolerated with some reports of 
gallstone formation [74, 75]. However, the lacking of clinical trials which test the long term 
use of somatostatin analogues along with the severe and adverse health implications such as 
decreased life expectancy due to accelerated heart disease which observed in adults with 
growth hormone deficiency may hinder its future use for leiomyoma treatment. 
8. Cabergoline 
Carbergoline is a well-known dopamine agonist that is effectively used in the treatment of 
prolactinoma and for the inhibition of lactation. A recent study [76] evaluated carbergoline 
as a therapeutic option for uterine fibroids. The rational for such an approach lies in its effect 
as an inhibitory agent on GnRH release. A group in Iran published a preliminary study in 
2007 [76] that favored the use of carbergoline as a medical treatment of uterine fibroids on 
which they reported a volume reduction of about 50% with 6 weeks use [65]. The same 
group performed a subsequent study that compared carbergoline with diphereline, which is 
a gonadotropin-releasing hormone agonist [77]. They reported comparable results in terms 
of the shrinkage of the fibroids and the improvement in the sonographic, clinical, and intra-
operative outcomes [77]. These findings warrant future larger controlled trials to clearly 
assess the potential use of carbergoline in the treatment of uterine fibroids.  
9. Danazol 
Danazol is a synthetic steroid that inhibits steroidogenesis through multi-enzymatic actions 
in addition to its suppressor effect on sex hormone binding globulin [78]. It reportedly 
induced a significant 24% volume reduction [79, 80]. However, a recent Cochrane study 
failed to identify any randomized controlled trials that compared danazol to placebo or any 
other medical therapy in women with uterine fibroids [81].  
9.1 Gestrinone 
Gestrinone is a steroid that possesses anti-estrogen receptor and anti-progesterone receptor 
properties in various tissues, including the endometrium [82]. A recent report from Italy 
evaluated the use of Gestrinone in the treatment of premenopausal women with uterine 
fibroids at a dose of 2.5 mg twice per week over a 6-month period [82]. The authors reported 
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a 32% ± 10% reduction in uterine volume [82]. A subsequent study reported up to 60% 
leiomyoma shrinkage in size [83]. Gestrinone is a contraceptive agent and also exhibits 
several unfavorable side effects, such as mild androgenicity, weight gain, seborrhea, acne, 
hirsutism, and occasional hoarseness. 
9.2 Vitamin D (VitD) 
Data from our laboratory demonstrate that Vitamin D (VitD) is an antifibrotic factor and 
inhibits growth and induces apoptosis in cultured human leiomyoma cells through the 
down-regulation of PCNA, CDK1, and BCL-2 and suppresses COMT expression and 
activity in human leiomyoma cells [84-86]. We have also recently demonstrated similar 
effects in the Eker rat model of uterine fibroids [87]. Another group in Finland demonstrated 
that Vitamin D inhibit growth of both myometrial and leiomyoma cells in vitro [88] The 
growth inhibition was concentration dependent and the level of inhibition was statistically 
significant with the concentration of 1000 nM.  
In a separate study from our group, the correlation between low serum levels of VitD and 
the increased risk of having symptomatic uterine fibroids were evaluated [89, 90]. We 
measured both the biologically active 1, 25 dihydroxyvitamin D3 and the precursor 25-
hydroxyvitamin D3 in the serum from African American and white women with fibroids as 
well as normal healthy controls. Interestingly, then observed that 1, 25 dihydroxyvitamin D3 
is significantly lower in women with fibroids compared to normal healthy controls; 
additionally, it has been detected that lower levels of total serum 25-hydroxyvitamin D3 in 
women with fibroids compared to healthy controls. These findings were observed both in 
African American women and in Caucasian women.  
The aim of the study was to determine whether serum levels of VitD correlated with disease 
severity in women with symptomatic uterine fibroids. The study population consisted of 67 
patients who had detailed repeated pelvic ultrasound evaluations over a 2-year period with 
specific measurements of the total uterine volume and the volume of the individual 
leiomyoma lesions. The patients also had detailed laboratory analysis including serum 25 
hydroxy Vit D3 levels. As shown in (Fig I), a statistically significant negative correlation 
between the low serum Vit D levels and the total uterine leiomyoma volume (P<.05) as well 
as the number of leiomyoma lesions/uterus (P<0.05) was detected [63]. Taken together, our 
preliminary results suggest a strong dose-response correlation between lower serum Vit D 
levels and increased severity of uterine fibroids. This presents an opportunity for the 
potential use of Vit D or its potent analogues as novel treatment options or for the 
prevention of uterine fibroids.  
To date there is no randomized controlled trials had been implemented to prospectively 
assess the efficacy of Vit D in the management of uterine fibroids. 
10. Epigallocatechin Gallate (EGCG), green tea extract 
Tea is one of the most widely consumed beverages all over the world. Both the green tea 
and the black tea are derived from the leaves of the plant ‘Camellia sinensis’ the most 
significant components of which are phytochemicals, of which Green tea is thoroughly 
studied for its health benefits.  
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A typical green tea beverage, prepared in a proportion of 1 g leaf to 100 ml water in a 3-min 
brew, usually contains 250–350mg tea solids, and catechins account for 30–42% of the dry 
weight of the solids [91]. It has been demonstrated that tea constituents exhibit various 
biological and pharmacological properties such anti-carcinogenic, antioxidative, anti-
allergic, anti-virus, anti-hypertensive, anti-atherosclerosis, anti-cardiovascular disease and 
anti-hypercholesterolemic activities [92, 93]. 
The major green tea catechins are epigallocatechin-3-gallate (EGCG), epigallocatechin 
(EGC), epicatechin-3-gallate (ECG) and epicatechin. Catechines are a group of bioflavonoids 
that exhibit antioxidant and anti-inflammatory capacity. Chemically, catechines are 
polyhydroxylated with water-soluble characteristics [94]. Epigallocatechin gallate (EGCG), 
which is the principal catechin, comprises >40% of the total polyphenolic mixture of green 
tea catechins [95], Grapes also contain polyphenols and catechins such as EGCG [96]. 
Epigallocatechin gallate exhibits various biological activities including potent antioxidant 
and anti-inflammation capacity [97].  
EGCG appears to block each stage of tumorgenesis by modulating signaling pathways 
involved in cell proliferation, transformation, inflammation, and oxidative stress, which are 
clearly involved in pathogenesis of various tumors including uterine fibroids [98]. 
In our laboratory, we studied the effect and potential mechanisms of EGCG action on 
human leiomyoma (HuLM) cells [99], as we assayed cell proliferation and apoptosis, the 
protein levels of PCNA, CDK4, BCL2, and BAX which examined by Western blot analysis, 
and we found that Epigallocatechin gallate inhibits the proliferation of HuLM cells and 
induces apoptosis. These results suggest that EGCG may be a potential anti-uterine fibroid 
agent acting through multiple signal transduction pathways [100]. Additional validation of 
these findings was achieved using orally administered EGCG to shrink pre-existing 
subcutaneous leiomyoma lesions in immune-compromised mice [99]. Previous studies have 
shown that EGCG inhibited the growth of various human cancer cells, such as epidermoid 
carcinoma cells [101], hepatoma cells [102], prostate carcinoma cells [103], and breast cancer 
cells [104]. Those findings motivated us to initiate a clinical trial to evaluate the promising 
clinical role of EGCG in women with symptomatic uterine fibroids. 
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